Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of IPI-204, A Novel Hsp90 Inhibitor in NSCLC Patients With ALK Translocations

NCT01228435 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01228435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01228435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of IPI-204, A Novel Hsp90 Inhibitor in NSCLC Patients With ALK Translocations
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2010
Completion date
February 29, 2012
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, stage iiib lung cancer, stage iv lung cancer